BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23384907)

  • 1. [Study on the role of fluorescence in situ hybridization in cytogenetic evaluation of myelodysplastic syndrome].
    Qu SQ; Xu ZF; Li CW; Liu XP; Qin TJ; Zhang Y; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):839-42. PubMed ID: 23384907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases.
    Coleman JF; Theil KS; Tubbs RR; Cook JR
    Am J Clin Pathol; 2011 Jun; 135(6):915-20. PubMed ID: 21571964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
    Cherry AM; Slovak ML; Campbell LJ; Chun K; Eclache V; Haase D; Haferlach C; Hildebrandt B; Iqbal AM; Jhanwar SC; Ohyashiki K; Sole F; Vandenberghe P; VanDyke DL; Zhang Y; Dewald GW
    Leuk Res; 2012 Jul; 36(7):832-40. PubMed ID: 22537394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure.
    Jiang H; Xue Y; Wang Q; Pan J; Wu Y; Zhang J; Bai S; Wang Q; He G; Sun A; Wu D; Chen S
    Leuk Res; 2012 Apr; 36(4):448-52. PubMed ID: 22047706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes?
    Yang W; Stotler B; Sevilla DW; Emmons FN; Murty VV; Alobeid B; Bhagat G
    Leuk Res; 2010 Apr; 34(4):420-5. PubMed ID: 19800120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional cytogenetics and fluorescence in situ hybridization in persistent cytopenias and myelodysplastic syndromes in childhood.
    Touliatou V; Kolialexi A; Tsangaris GT; Moschovi M; Polychronopoulou S; Mavrou A
    Anticancer Res; 2004; 24(6):3945-9. PubMed ID: 15736436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative study of fluorescence in situ hybridization versus conventional cytogenetics in the detection of clonal aberrations in myelodysplastic syndrome].
    Lai YY; Li N; Feng L; Shi Y; Dang H; He Q; Wang Z; Wang XY; Li Y; Liu Q; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3175-9. PubMed ID: 24405535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China.
    Lai YY; Huang XJ; Li J; Zou P; Xu ZF; Sun H; Shao ZH; Zhou DB; Chen FP; Liu ZG; Zhu HL; Wu DP; Wang C; Zhang Y; Li Y; Hou M; Du X; Wang X; Li W; Lai YR; Zhou J; Zhou YH; Fang MY; Qiu L; Wang XM; Zhang GS; Jiang M; Liang YM; Zhang LS; Chen XQ; Bai H; Lin JY
    Leuk Res; 2015 May; 39(5):530-5. PubMed ID: 25823643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
    Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hidden chromosome 8 abnormalities detected by FISH in adult primary myelodysplastic syndromes.
    Panani AD; Pappa V
    In Vivo; 2005; 19(6):979-81. PubMed ID: 16277010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization:  Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.
    He R; Wiktor AE; Durnick DK; Kurtin PJ; Van Dyke DL; Tefferi A; Patnaik MS; Ketterling RP; Hanson CA
    Am J Clin Pathol; 2016 Jul; 146(1):86-94. PubMed ID: 27353768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
    Braulke F; Jung K; Schanz J; Götze K; Müller-Thomas C; Platzbecker U; Germing U; Brümmendorf TH; Bug G; Ottmann O; Giagounidis AA; Stadler M; Hofmann WK; Schafhausen P; Lübbert M; Schlenk RF; Blau IW; Ganster C; Pfeiffer S; Shirneshan K; Metz M; Detken S; Seraphin J; Jentsch-Ullrich K; Böhme A; Schmidt B; Trümper L; Haase D
    Leuk Res; 2013 Aug; 37(8):900-6. PubMed ID: 23623559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients.
    Bernasconi P; Cavigliano PM; Boni M; Calatroni S; Klersy C; Giardini I; Rocca B; Crosetto N; Caresana M; Lazzarino M; Bernasconi C
    Leukemia; 2003 Nov; 17(11):2107-12. PubMed ID: 12931223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics.
    Kokate P; Dalvi R; Koppaka N; Mandava S
    Cancer Genet; 2017 Oct; 216-217():120-127. PubMed ID: 29025586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes.
    Kawankar N; Jijina F; Ghosh K; Vundinti BR
    Cancer Epidemiol; 2011 Aug; 35(4):e1-5. PubMed ID: 21193364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.
    Braulke F; Schanz J; Jung K; Shirneshan K; Schulte K; Schuetze C; Steffens R; Trümper L; Haase D
    Leuk Res; 2010 Oct; 34(10):1296-301. PubMed ID: 20226527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.